Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced hepatocellular carcinoma
1 finding from 1 review
Disease progression · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Intervention not reported
Supportive care only*** (1 RCT, 81 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
1 finding from 1 review
ACT use (percentage of children under 5 years receiving ACT on the same day or following day of fever onset) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT availability (percentage of outlets stocking ACTs for children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
ACT availability (percentage of outlets stocking at least one ACT for patients of any age) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
ACT price (change in ACT prices for children under 5 years)c · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
Use of older antimalarials (amodiaquine, sulphadoxine‐pyrimethamine; children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Adverse effects (such as the number of people receiving ACTs who do not have malaria) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
Progression to oxygen therapy · people with confirmed COVID‐19
Favipiravir showed no clear difference in progression to oxygen therapy compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to lower overall survival (low certainty).
1 finding from 1 review
Intervention not reported
Toxic death · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Adverse effects · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to higher quality of life (low certainty).
1 finding from 1 review